Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shares Down 6.2% – Time to Sell?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) shares dropped 6.2% during mid-day trading on Monday . The company traded as low as $39.44 and last traded at $39.4220. Approximately 90,020 shares were traded during mid-day trading, a decline of 76% from the average daily volume of 369,847 shares. The stock had previously closed at $42.01.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. TD Cowen assumed coverage on Kiniksa Pharmaceuticals International in a report on Monday, September 29th. They set a “buy” rating and a $60.00 price target on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Wedbush reissued an “outperform” rating and set a $48.00 price target on shares of Kiniksa Pharmaceuticals International in a research note on Tuesday, December 2nd. Finally, Wells Fargo & Company upped their target price on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an “overweight” rating in a research report on Thursday, September 25th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $52.00.

Kiniksa Pharmaceuticals International Trading Down 2.7%

The firm’s fifty day moving average price is $40.88 and its 200 day moving average price is $35.93. The firm has a market capitalization of $3.10 billion, a PE ratio of 90.59 and a beta of 0.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.08). The company had revenue of $180.86 million for the quarter, compared to analyst estimates of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.Kiniksa Pharmaceuticals International’s revenue for the quarter was up 61.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.18) earnings per share. On average, analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, insider John F. Paolini sold 82,542 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Friday, October 31st. The shares were sold at an average price of $37.14, for a total transaction of $3,065,609.88. Following the completion of the transaction, the insider directly owned 61,324 shares of the company’s stock, valued at $2,277,573.36. The trade was a 57.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Eben Tessari sold 12,048 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, December 15th. The shares were sold at an average price of $41.56, for a total transaction of $500,714.88. Following the completion of the transaction, the chief operating officer directly owned 16,666 shares of the company’s stock, valued at $692,638.96. The trade was a 41.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 511,057 shares of company stock worth $19,972,512. 53.48% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KNSA. EverSource Wealth Advisors LLC raised its position in shares of Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after purchasing an additional 532 shares during the last quarter. Osaic Holdings Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter worth approximately $31,000. USA Financial Formulas purchased a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter worth approximately $32,000. Quantbot Technologies LP purchased a new stake in shares of Kiniksa Pharmaceuticals International during the second quarter worth approximately $43,000. Finally, Quarry LP purchased a new position in Kiniksa Pharmaceuticals International in the 3rd quarter valued at $44,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.